M'kacher Radhia, Frenzel Monika, Al Jawhari Mustafa, Junker Steffen, Cuceu Corina, Morat Luc, Bauchet Anne-Laure, Stimmer Lev, Lenain Aude, Dechamps Nathalie, Hempel William M, Pottier Geraldine, Heidingsfelder Leonhard, Laplagne Eric, Borie Claire, Oudrhiri Noufissa, Jouni Dima, Bennaceur-Griscelli Annelise, Colicchio Bruno, Dieterlen Alain, Girinsky Theodore, Boisgard Raphael, Bourhis Jean, Bosq Jacques, Mehrling Thomas, Jeandidier Eric, Carde Patrice
Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
Cell Environment, Oncology Section, 75020 Paris, France.
Cancers (Basel). 2018 Oct 31;10(11):414. doi: 10.3390/cancers10110414.
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30-/CD15- cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (-/-)(NSG) mice. Using cell sorting, we demonstrate that CD30-/CD15- subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30-/CD15- cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Our HL animal model requires only 10³ cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30-/CD15- cells exhibiting high telomerase activity and telomere dysfunction.
为了确定引发和维持霍奇金淋巴瘤(HL)细胞的细胞,我们对在体外和体内生长的HL细胞亚群进行了表征,目的是建立一个可靠且强大的HL动物模型。为了验证我们的模型,我们通过向异种移植小鼠注射烷化组蛋白脱乙酰酶抑制剂EDO-S101(一种HL患者的挽救方案)来在体内挑战肿瘤细胞。使用了50例HL患者的血液淋巴细胞和7种HL细胞系。进行了免疫组织化学、流式细胞术和细胞遗传学分析。评估了EDO-S101的体外和体内作用。我们成功确定了HL L428-c亚系的体外扩增和表征条件,该亚系中CD30-/CD15-细胞的比例高于亲本L428细胞系。将该亚系异种移植到免疫缺陷的NOD-SCID-γ(-/-)(NSG)小鼠中时,显示出优异的克隆形成潜力和可靠的可重复性。通过细胞分选,我们证明CD30-/CD15-亚群在体外可获得L428-c细胞系的表型。此外,将L428-c细胞注射到NSG小鼠中7周后回收的人细胞是小细胞,其特征是CD30-/CD15-细胞频率高。细胞遗传学分析表明它们是二倍体,并表现出高端粒不稳定性和端粒酶活性。因此,出现了染色体不稳定性,表现为双着丝粒染色体、环状染色体以及断裂/融合/桥循环的形成。同样,在HL患者的循环淋巴细胞中检测到了高端粒酶活性和端粒不稳定性。组蛋白脱乙酰酶抑制剂EDO-S101作为抗肿瘤药物的有益作用验证了我们 的动物模型。我们的HL动物模型仅需要10³个细胞,其特征是高生存/毒性比和高可重复性。此外,植入小鼠体内的细胞的特征是小CD30-/CD15-细胞频率高,表现出高端粒酶活性和端粒功能障碍。